logo

For the Inventor, By the Inventor

Holte, Denmark

Kennett Sprogøe

This inventor holds 30 USPTO granted patents and 36 published patent applications, primarily in Controlled-Release Therapies. Top assignees: Ascendis Pharma Bone Diseases A/s, Ascendis Pharma Growth Disorders A/s, Ascendis Pharma A/s. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kennett Sprogøe. Retrieved from https://idiyas.com/inventor/kennett-sprogøe

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 

% Patents Active = 93.3

Average Co-Inventor Count = 4.6

ph-index = 5

Forward Citations = 80(Granted Patents)


Location History:

  • Palo Alto, CA (US) (2014 - 2021)
  • Holte, DK (2017 - 2024)

Company Filing History:

goldMedal10 out of 10 
 
Ascendis Pharma Bone Diseases A/s
 patents
silverMedal10 out of 14 
 
Ascendis Pharma Growth Disorders A/s
 patents
bronzeMedal5 out of 48 
 
Ascendis Pharma A/s
 patents
4. 4 out of 9 
 
Ascendis Pharma Endocrinology Division A/s
 patents
5. 1 out of 1 
 
Ascendis Pharma Ophthalmology Division A/s
 patent

Years Active: 2014-2026

Loading Chart...
Areas of Expertise:
Controlled-Release
CNP Agonists
PTH Compounds
PEGylated Hormones
Growth Hormone
Prodrugs
Sustained Release
Combination Therapy
Pharmaceutical Formulations
Dosage Regimen
Ocular Treatments
Treprostinil
30 patents (USPTO):Explore Patents
1. 12667604 - Combination Therapy with Controlled-Release CNP Agonists (2026-06-30),
2. 12544428 - CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS (2026-02-10),
3. 12453778 - Incremental dose finding in controlled-release PTH compounds (2025-10-28),
4. 12403182 - Liquid pharmaceutical formulations of PTH conjugates (2025-09-02),
5. 12303553 - Long-acting growth hormone dosage forms with superior efficacy to daily somatropin (2025-05-20),
6. 12295989 - Controlled-release PTH compound (2025-05-13),
7. 12274737 - PEGylated recombinant human growth hormone compounds (2025-04-14),
8. 12239689 - Controlled-release CNP agonists with low initial NPR-B activity (2025-03-04),
9. 12214020 - PTH prodrugs (2025-02-04),
10. 12156917 - CNP prodrugs with carrier attachment at the ring moiety (2024-12-03),
11. 12083182 - Controlled-release CNP agonists with increased NEP stability (2024-09-10),
12. 12016903 - Long-acting growth hormone treatment (2024-06-25),
13. 11918628 - Controlled-release PTH compound (2024-03-05),
14. 11890326 - Controlled-release PTH compound (2024-02-06),
15. 11857603 - PTH compounds with low peak-to-trough ratios (2024-01-02),

Title: Kennett Sprogøe - The Innovative Mind from Holte

Introduction: Kennett Sprogøe, a distinguished inventor hailing from Holte, Denmark, is renowned for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Kennett Sprogøe's latest patents focus on advancements in renewable energy technologies, particularly in the development of solar-powered devices for sustainable living.

Career Highlights: Throughout his illustrious career, Kennett Sprogøe has been instrumental in creating cutting-edge solutions for environmental challenges, earning him recognition as a pioneer in the green technology sector.

Collaborations: Kennett Sprogøe has collaborated with leading research institutions and universities worldwide to further his innovative projects, showcasing his commitment to fostering collaboration and knowledge-sharing in the industry.

Conclusion: Kennett Sprogøe's passion for innovation and dedication to creating a more sustainable future through his inventive work continue to inspire and shape the landscape of technological advancements globally.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…